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(CLI) eventually require amputation. In spite of clinically
successful revascularisation patients rarely return to their
pre-morbid status, and often report no improvement in
their functional outcomes, which may be due to an un-
derlying musculopathy. Non-haematopoietic EPO-de-
rivatives have been designed to retain only tissue-protective
functions of EPO. We hypothesised that ARA-290 (EPO-de-
rivative) may have tissue-protective potential that would
represent a novel therapeutic adjunct in patients with CLI.
Methods: The effect of EPO and ARA-290 in mediating
cytoprotection was assessed ﬁrstly in vitro using skeletal
myoblasts isolated from CLI and control donors, and a
model of simulated ischaemia. Characterisation of CLI
myoblasts was also performed, to assess their contractile,
migratory and proliferative ability. Subsequently, an in vivo
murine model of hindlimb ischaemia, which recapitulates
the muscular pathology observed in CLI patients, was used
to assess the potential of ARA-290 to improve functional,
histological and perfusion outcomes.
Results: Skeletal myoblasts were successfully isolated from
CLI patients for the ﬁrst time. CLI myoblasts and myotubes
exhibited increased proliferative capacity but reduced
migratory and contractile function and importantly a
reduced susceptibility to a second ischaemic-insult
compared with control myoblasts and myotubes. EPO and
ARA-290 treatment led to signiﬁcant improvements in
myoblasts and myotube function and survival via the JAK2/
STAT3, PI3k/Akt and NFkB signalling pathways. In vivo,
animals treated with EPO and ARA-290 demonstrated
improved functional, histological and perfusion outcomes
compared to vehicle-control treated animals.
Conclusion: These studies demonstrate the potential of EPO
and its derivatives to protect tissues and cells from
ischaemic-injury and encourages the development of novel
pharmacological therapies for use in patients with “no op-
tion” CLI or severe functional deﬁcit.
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Introduction: Immature plaque neovessels contribute to
atherosclerotic plaque instability and intraplaque hemor-
rhage by leaking erythrocytes and leukocytes in the plaque.
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2),
together with the angiopoietin (Ang)-Tie2 system, regulates
the maturation of growing neovessels. We have previously
shown that murine vein graft lesions exhibit massive plaqueneovascularization and that leaky vessels and intraplaque
hemorrhage contribute to lesion growth. We hypothesized
that blockade of VEGFR2 results in more mature plaque
microvessels and less intraplaque hemorrhage.
Methods: Donor caval veins were engrafted in carotid ar-
teries of recipient hypercholesterolemic ApoE3*Leiden mice
(n ¼ 14/group). Mice were treated at day 14, 17, 21 and 25
with VEGFR2 blocking antibodies (DC101) or control IgG
antibodies (10 mg/kg). At day 28 mice were sacriﬁced for
histological analysis of the vein grafts.
Results: Morphometric analysis revealed a striking 50%
decrease in vein graft segments that expressed intraplaque
haemorrhage in the form of leaky vessels in the DC101
treated group. This was accompanied by a signiﬁcant 25-
fold decrease in extravasated erythrocytes. Furthermore,
lesions that exhibit intraplaque hemorrhage showed a
strong increase in Ang-2, indicative for immature neo-
vessels. VEGFR2 blockade however, did not affect the neo-
vessel density in the lesions (control 52  19 neovessels/
section; DC101 63  25 neovessels/section). Interestingly,
the vein graft lesion area in the DC101 group was signiﬁ-
cantly reduced with 32% compared to the control group.
Moreover, plaque stability was clearly increased in DC101
treated mice, determined by a 25% reduction in macro-
phage content, a 50% increase in collagen content and a
120% increase in SMC content.
Conclusion: Blockade of VEGFR2 leads to reduced intra-
plaque hemorrhage, decreased vein graft lesion area and
increased plaque stability. This identiﬁes plaque neo-
vascularization as an attractive target for the treatment of
unstable atherosclerotic diseases.
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Introduction: TLR4-mediated mobilisation and activation of
pro-inﬂammatory Ly6Chi monocytes is crucial for effective
post-ischemic neovascularisation, i.e. arteriogenesis and
angiogenesis. Therefore, we aimed to investigate the role of
the TLR4-accessory molecule RP105 (CD180) in neo-
vascularisation. RP105 has been identiﬁed as a negative
regulator of TLR4 signalling in monocytes. Using immuno-
histochemical analyses, we found that RP105+monocytes are
present in the perivascular space of remodelling collateral
arterioles. As RP105 inhibits TLR4 signalling, we hypothesized
that RP105 deﬁciency would lead to an unrestrained TLR4-
mediated inﬂammatory response and hence to enhanced
neovascularisation and blood ﬂow recovery after ischemia.
Methods: RP105/ and wildtype mice were subjected to
hind limb ischemia and blood ﬂow recovery was followed
by Laser Doppler Perfusion Imaging during four weeks.
